Loading patent…
AssigneeNortheastern University
InventorsTania KONRY, Matthew SULLIVAN
Estimating the term…
The present technology provides a genetically modified immune cell expressing a chimeric antigen receptor (CAR) and also expressing an elevated level of a ligand for a tumor necrosis factor (TNF) receptor. The genetically modified cell takes advantage of dual pathways for killing cancer cells, cellular pathogens, and cells infected with viruses. The CAR-mediated pathway promotes killing action by perforin and granzymes released by cytotoxic T lymphocytes and natural killer cells, as well as the TNF receptor (i.e., death domain) mediated target cell killing by these same cells. Further, the present technology, especially when combined with single cell image analysis, microfluidics based cell sorting, and transcriptomic analysis makes it possible to adapt genetic modifications to cells of a patient, in response to significant patient to patient variation in gene expression of T cells and NK cells.
A genetically modified immune cell expressing a chimeric antigen receptor (CAR) and an elevated level of a ligand for a tumor necrosis factor (TNF) receptor.
A kit comprising one or more viral vectors for genetically modifying an immune cell to express a CAR and to elevate an expression level of a ligand for a TNF receptor, and instructions or one or more reagents for carrying out the genetic modification.
A method of producing a genetically modified cell, the method comprising:
Dependencies are inferred from the claim text.